Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study

Lignende værker

• Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study
  af: Masaki Kanazu, et al.
  Udgivet: (2021-01-01)
• The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
  af: Tamiya, Motohiro, et al.
  Udgivet: (2021)
• A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation
  af: Imamura, Fumio, et al.
  Udgivet: (2016)
• Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment
  af: Imamura, Fumio, et al.
  Udgivet: (2016)
• Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
  af: Imamura, Fumio, et al.
  Udgivet: (2020)